Reproductive Health Therapeutics
1. Addyi patent expiration
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7420057 | SPROUT PHARMS | Stable polymorph of flibanserin |
Aug, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8227471 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
May, 2023
(2 years ago) | |
| US9468639 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
Oct, 2022
(3 years ago) | |
| US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 18, 2020 |
Drugs and Companies using FLIBANSERIN ingredient
NCE-1 date: 19 August, 2019
Market Authorisation Date: 18 August, 2015
Dosage: TABLET
More Information on Dosage
ADDYI family patents
2. Bextra patent expiration
Treatment: Signs and symptoms of osteoarthritis and adult rheumatoid arthritis and treatment of primary dysmenorrhea
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5633272 | GD SEARLE | Substituted isoxazoles for the treatment of inflammation |
Feb, 2015
(10 years ago) | |
Drugs and Companies using VALDECOXIB ingredient
Market Authorisation Date: 16 November, 2001
Dosage: TABLET
More Information on Dosage
BEXTRA family patents
3. Cetrotide patent
expiration
Treatment: Prevention of premature lh surges in women undergoing controlled ovarian stimulation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6319192 | EMD SERONO INC | Method for the treatment of fertility disorders |
Apr, 2019
(6 years ago) | |
| US6863891 | EMD SERONO INC | Oligopeptide lyophilisate, their preparation and use |
Feb, 2014
(11 years ago) | |
| US7605121 | EMD SERONO INC | Oligopeptide lyophilisate, their preparation and use |
Feb, 2014
(11 years ago) | |
Drugs and Companies using CETRORELIX ACETATE ingredient
Market Authorisation Date: 11 August, 2000
Dosage: POWDER
More Information on Dosage
CETROTIDE family patents
4. Ella patent expiration
Treatment: Method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of ...
ELLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962603 | LAB HRA PHARMA | Method for post coital contraception in overweight or obese female subjects using ulipristal acetate |
Jun, 2030
(4 years from now) | |
| US8426392 | LAB HRA PHARMA | Method for providing emergency contraception |
Jun, 2030
(4 years from now) | |
| US9283233 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(4 years from now) | |
| US10159681 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(4 years from now) | |
| US10772897 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(4 years from now) | |
| US8735380 | LAB HRA PHARMA | Ulipristal acetate tablets |
Feb, 2029
(3 years from now) | |
| US9844510 | LAB HRA PHARMA | Ulipristal acetate tablets |
Dec, 2028
(2 years from now) | |
| US8512745 | LAB HRA PHARMA | Ulipristal acetate tablets |
Jun, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2015 |
| M(M-271) | Jun 24, 2024 |
Drugs and Companies using ULIPRISTAL ACETATE ingredient
NCE-1 date: 13 August, 2014
Market Authorisation Date: 13 August, 2010
Dosage: TABLET
How can I launch a generic of ELLA before it's drug patent expiration?
More Information on Dosage
ELLA family patents
5. Orilissa patent expiration
Treatment: Management of moderate to severe pain associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150 mg or 200 mg elagolix while co-administering omeprazo...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6872728 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(4 years ago) | |
| US7462625 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(4 years ago) | |
| US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(1 year, 3 months ago) | |
| US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(13 years from now) | |
| US7419983 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7179815 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Mar, 2021
(4 years ago) | |
| US7176211 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(1 year, 6 months ago) | |
| US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(14 years from now) | |
| US10537572 | ABBVIE | Methods of administering elagolix |
Sep, 2036
(10 years from now) | |
| US10682351 | ABBVIE | Methods of administering elagolix |
Sep, 2036
(10 years from now) | |
| US11690854 | ABBVIE | Methods of treating heavy menstrual bleeding |
Apr, 2038
(12 years from now) | |
| US11344551 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(8 years from now) | |
| US11707464 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(8 years from now) | |
| US12102637 | ABBVIE | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
Aug, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Dosage: TABLET
How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage
ORILISSA family patents